![](https://static.wixstatic.com/media/cd6738_dc891e37a69d413ab775787a04c1ede4~mv2.jpg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/cd6738_dc891e37a69d413ab775787a04c1ede4~mv2.webp)
![NCT04653246: Phase 2: Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM](https://static.wixstatic.com/media/cd6738_dc891e37a69d413ab775787a04c1ede4~mv2.jpg/v1/fill/w_268,h_179,fp_0.50_0.50,q_90,enc_auto/cd6738_dc891e37a69d413ab775787a04c1ede4~mv2.webp)
NCT04653246: Phase 2: Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM
![](https://static.wixstatic.com/media/cd6738_7930363630d44d638e62802fde2d858d~mv2.jpeg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/cd6738_7930363630d44d638e62802fde2d858d~mv2.webp)
![NCT04586426: Phase 1b - Talquetamab and Teclistamab in Relapsed or Refractory Multiple Myeloma](https://static.wixstatic.com/media/cd6738_7930363630d44d638e62802fde2d858d~mv2.jpeg/v1/fill/w_268,h_182,fp_0.50_0.50,q_90,enc_auto/cd6738_7930363630d44d638e62802fde2d858d~mv2.webp)
NCT04586426: Phase 1b - Talquetamab and Teclistamab in Relapsed or Refractory Multiple Myeloma
![](https://static.wixstatic.com/media/cd6738_5535fac1a57c4e1ca9ec652aa5c82bbc~mv2.jpg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/cd6738_5535fac1a57c4e1ca9ec652aa5c82bbc~mv2.webp)
![NCT04552743: Phase 2: MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for ASCT](https://static.wixstatic.com/media/cd6738_5535fac1a57c4e1ca9ec652aa5c82bbc~mv2.jpg/v1/fill/w_268,h_181,fp_0.50_0.50,q_90,enc_auto/cd6738_5535fac1a57c4e1ca9ec652aa5c82bbc~mv2.webp)
NCT04552743: Phase 2: MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for ASCT
![](https://static.wixstatic.com/media/cd6738_f8686c5834394143b6cd00c8c18123d3~mv2.jpg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/cd6738_f8686c5834394143b6cd00c8c18123d3~mv2.webp)
![NCT04649359: Phase 2 - MagnetisMM-3: Elranatamab (PF-06863135) Monotherapy in relapsed Myeloma](https://static.wixstatic.com/media/cd6738_f8686c5834394143b6cd00c8c18123d3~mv2.jpg/v1/fill/w_268,h_180,fp_0.50_0.50,q_90,enc_auto/cd6738_f8686c5834394143b6cd00c8c18123d3~mv2.webp)
NCT04649359: Phase 2 - MagnetisMM-3: Elranatamab (PF-06863135) Monotherapy in relapsed Myeloma
![](https://static.wixstatic.com/media/cd6738_7cbdd623ede4481584ade2172f4c5bce~mv2.jpg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/cd6738_7cbdd623ede4481584ade2172f4c5bce~mv2.webp)
![NCT04436029: Phase 2: Descartes-11 Consolidation Treatment Patients With High-Risk Multiple Myeloma](https://static.wixstatic.com/media/cd6738_7cbdd623ede4481584ade2172f4c5bce~mv2.jpg/v1/fill/w_268,h_179,fp_0.50_0.50,q_90,enc_auto/cd6738_7cbdd623ede4481584ade2172f4c5bce~mv2.webp)
NCT04436029: Phase 2: Descartes-11 Consolidation Treatment Patients With High-Risk Multiple Myeloma
![](https://static.wixstatic.com/media/cd6738_d7cc15c5a6b34ecd934ac47ef6e4c256~mv2.jpeg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/cd6738_d7cc15c5a6b34ecd934ac47ef6e4c256~mv2.webp)
![FDA Approved for RRMM: Darzalex (Daratumumab) + Kyprolis (Carfilzomib) and Dexamethasone (Dara-Kd)](https://static.wixstatic.com/media/cd6738_d7cc15c5a6b34ecd934ac47ef6e4c256~mv2.jpeg/v1/fill/w_268,h_268,fp_0.50_0.50,q_90,enc_auto/cd6738_d7cc15c5a6b34ecd934ac47ef6e4c256~mv2.webp)
FDA Approved for RRMM: Darzalex (Daratumumab) + Kyprolis (Carfilzomib) and Dexamethasone (Dara-Kd)
![](https://static.wixstatic.com/media/cd6738_7c9fdfe770a04e5bbbe9ef762fd22e29~mv2.jpg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/cd6738_7c9fdfe770a04e5bbbe9ef762fd22e29~mv2.webp)
![NCT04268498: Phase2 - Daratumumab, Carfilzomib, Lenalidomide, Dex NDMM Multiple Myeloma (ADVANCE)](https://static.wixstatic.com/media/cd6738_7c9fdfe770a04e5bbbe9ef762fd22e29~mv2.jpg/v1/fill/w_268,h_178,fp_0.50_0.50,q_90,enc_auto/cd6738_7c9fdfe770a04e5bbbe9ef762fd22e29~mv2.webp)
NCT04268498: Phase2 - Daratumumab, Carfilzomib, Lenalidomide, Dex NDMM Multiple Myeloma (ADVANCE)
![](https://static.wixstatic.com/media/cd6738_dbb18e2db4a643ce8bae5021f6d27485~mv2.jpg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/cd6738_dbb18e2db4a643ce8bae5021f6d27485~mv2.webp)
![NCT04352205: Phase 2: Daratumumab-Based Therapy for NDMM Multiple Myeloma with Kidney failure](https://static.wixstatic.com/media/cd6738_dbb18e2db4a643ce8bae5021f6d27485~mv2.jpg/v1/fill/w_268,h_182,fp_0.50_0.50,q_90,enc_auto/cd6738_dbb18e2db4a643ce8bae5021f6d27485~mv2.webp)
NCT04352205: Phase 2: Daratumumab-Based Therapy for NDMM Multiple Myeloma with Kidney failure
![](https://static.wixstatic.com/media/cd6738_3eb4f4c3836c4194adeb0d77239e31bc~mv2.jpeg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/cd6738_3eb4f4c3836c4194adeb0d77239e31bc~mv2.webp)
![NCT04459416: Phase 3: Managing Pain and Symptom Burden Caused by Chemotherapy in Myeloma or Lymphoma](https://static.wixstatic.com/media/cd6738_3eb4f4c3836c4194adeb0d77239e31bc~mv2.jpeg/v1/fill/w_268,h_180,fp_0.50_0.50,q_90,enc_auto/cd6738_3eb4f4c3836c4194adeb0d77239e31bc~mv2.webp)
NCT04459416: Phase 3: Managing Pain and Symptom Burden Caused by Chemotherapy in Myeloma or Lymphoma
![](https://static.wixstatic.com/media/cd6738_9fc925979cc0403a94df0c3b12de9a51~mv2.jpeg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/cd6738_9fc925979cc0403a94df0c3b12de9a51~mv2.webp)
![NCI - National Cancer Institute : How Monoclonal Antibodies Treat Cancer?](https://static.wixstatic.com/media/cd6738_9fc925979cc0403a94df0c3b12de9a51~mv2.jpeg/v1/fill/w_268,h_151,fp_0.50_0.50,q_90,enc_auto/cd6738_9fc925979cc0403a94df0c3b12de9a51~mv2.webp)
NCI - National Cancer Institute : How Monoclonal Antibodies Treat Cancer?
![](https://static.wixstatic.com/media/cd6738_c0a213f53fe74548977d8b93cf45c51a~mv2.jpg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/cd6738_c0a213f53fe74548977d8b93cf45c51a~mv2.webp)
![NYC-Miami Myeloma MRD 2020 Virtual Meeting, 8th of October 2020](https://static.wixstatic.com/media/cd6738_c0a213f53fe74548977d8b93cf45c51a~mv2.jpg/v1/fill/w_268,h_151,fp_0.50_0.50,q_90,enc_auto/cd6738_c0a213f53fe74548977d8b93cf45c51a~mv2.webp)
NYC-Miami Myeloma MRD 2020 Virtual Meeting, 8th of October 2020
![](https://static.wixstatic.com/media/cd6738_47f8a13afd4b48cc96d804d9eb769116~mv2.jpg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/cd6738_47f8a13afd4b48cc96d804d9eb769116~mv2.webp)
![EHA25 Virtual : Congress of the European Hematology Association - June 11 - 21, 2020](https://static.wixstatic.com/media/cd6738_47f8a13afd4b48cc96d804d9eb769116~mv2.jpg/v1/fill/w_268,h_235,fp_0.50_0.50,q_90,enc_auto/cd6738_47f8a13afd4b48cc96d804d9eb769116~mv2.webp)
EHA25 Virtual : Congress of the European Hematology Association - June 11 - 21, 2020
![NCT04394650: Phase 1 - CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in RRMM](https://static.wixstatic.com/media/cd6738_21036bfba45e48e79fa62a94ce1a8c3a~mv2.png/v1/fill/w_268,h_180,fp_0.50_0.50,q_95,enc_auto/cd6738_21036bfba45e48e79fa62a94ce1a8c3a~mv2.webp)
NCT04394650: Phase 1 - CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in RRMM
![](https://static.wixstatic.com/media/cd6738_b908e7c58bf84cb487e3a5710190b5a0~mv2.jpeg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/cd6738_b908e7c58bf84cb487e3a5710190b5a0~mv2.webp)
![Allogenic CAR T Explained by Precision BioSciences](https://static.wixstatic.com/media/cd6738_b908e7c58bf84cb487e3a5710190b5a0~mv2.jpeg/v1/fill/w_268,h_191,fp_0.50_0.50,q_90,enc_auto/cd6738_b908e7c58bf84cb487e3a5710190b5a0~mv2.webp)
Allogenic CAR T Explained by Precision BioSciences
![](https://static.wixstatic.com/media/cd6738_68f707513b3c4cc0944a61b92aa144a0~mv2.jpeg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/cd6738_68f707513b3c4cc0944a61b92aa144a0~mv2.webp)
![FDA Approved for RRMM:Daratumumab and Hyaluronidase-fihj (Darzalex Faspro) + Velcade & Dexamethasone](https://static.wixstatic.com/media/cd6738_68f707513b3c4cc0944a61b92aa144a0~mv2.jpeg/v1/fill/w_268,h_268,fp_0.50_0.50,q_90,enc_auto/cd6738_68f707513b3c4cc0944a61b92aa144a0~mv2.webp)
FDA Approved for RRMM:Daratumumab and Hyaluronidase-fihj (Darzalex Faspro) + Velcade & Dexamethasone
![](https://static.wixstatic.com/media/cd6738_bb9a041a1777447d9bf1a62dbba1e4df~mv2.jpeg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/cd6738_bb9a041a1777447d9bf1a62dbba1e4df~mv2.webp)
![Daratumumab / Hyaluronidase-fihj (Darzalex Faspro) + Lenalidomide (Revlimid)+ Dexamethasone for NDMM](https://static.wixstatic.com/media/cd6738_bb9a041a1777447d9bf1a62dbba1e4df~mv2.jpeg/v1/fill/w_268,h_268,fp_0.50_0.50,q_90,enc_auto/cd6738_bb9a041a1777447d9bf1a62dbba1e4df~mv2.webp)
Daratumumab / Hyaluronidase-fihj (Darzalex Faspro) + Lenalidomide (Revlimid)+ Dexamethasone for NDMM
![](https://static.wixstatic.com/media/cd6738_728f457ce46147b79f53c7f962663987~mv2.jpeg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/cd6738_728f457ce46147b79f53c7f962663987~mv2.webp)
![Response-adapted lenalidomide maintenance in newly diagnosed myeloma: phase III GMMG-MM5 trial](https://static.wixstatic.com/media/cd6738_728f457ce46147b79f53c7f962663987~mv2.jpeg/v1/fill/w_268,h_180,fp_0.50_0.50,q_90,enc_auto/cd6738_728f457ce46147b79f53c7f962663987~mv2.webp)
Response-adapted lenalidomide maintenance in newly diagnosed myeloma: phase III GMMG-MM5 trial
![](https://static.wixstatic.com/media/cd6738_92386fcd40294fafb6e0da34414385d0~mv2.jpg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/cd6738_92386fcd40294fafb6e0da34414385d0~mv2.webp)
![NCT04236011: Phase 1: BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Myeloma](https://static.wixstatic.com/media/cd6738_92386fcd40294fafb6e0da34414385d0~mv2.jpg/v1/fill/w_268,h_182,fp_0.50_0.50,q_90,enc_auto/cd6738_92386fcd40294fafb6e0da34414385d0~mv2.webp)
NCT04236011: Phase 1: BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Myeloma
![](https://static.wixstatic.com/media/cd6738_ba7f40f64dba43f88d30fa0b27b90336~mv2.jpg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/cd6738_ba7f40f64dba43f88d30fa0b27b90336~mv2.webp)
![Myeloma UK Publication, intended for UK Audience: Infopack for newly diagnosed patients](https://static.wixstatic.com/media/cd6738_ba7f40f64dba43f88d30fa0b27b90336~mv2.jpg/v1/fill/w_268,h_151,fp_0.50_0.50,q_90,enc_auto/cd6738_ba7f40f64dba43f88d30fa0b27b90336~mv2.webp)
Myeloma UK Publication, intended for UK Audience: Infopack for newly diagnosed patients
![](https://static.wixstatic.com/media/cd6738_191724767a1b48928e9b188975721e6f~mv2.jpeg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/cd6738_191724767a1b48928e9b188975721e6f~mv2.webp)
![NCT04302324: Phase 2: Daratumumab, Clarithromycin, Pomalidomide And Dex RRMM - D-ClaPd](https://static.wixstatic.com/media/cd6738_191724767a1b48928e9b188975721e6f~mv2.jpeg/v1/fill/w_268,h_180,fp_0.50_0.50,q_90,enc_auto/cd6738_191724767a1b48928e9b188975721e6f~mv2.webp)
NCT04302324: Phase 2: Daratumumab, Clarithromycin, Pomalidomide And Dex RRMM - D-ClaPd
![](https://static.wixstatic.com/media/cd6738_4ad75a598e524b2596ca40bcf0954d94~mv2.jpg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/cd6738_4ad75a598e524b2596ca40bcf0954d94~mv2.webp)
![The 20/2/20 risk stratification model for Smoldering Myeloma](https://static.wixstatic.com/media/cd6738_4ad75a598e524b2596ca40bcf0954d94~mv2.jpg/v1/fill/w_268,h_268,fp_0.50_0.50,q_90,enc_auto/cd6738_4ad75a598e524b2596ca40bcf0954d94~mv2.webp)
The 20/2/20 risk stratification model for Smoldering Myeloma
![](https://static.wixstatic.com/media/cd6738_3a04cda6865044f9ac2de8c216d60d69~mv2.jpg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/cd6738_3a04cda6865044f9ac2de8c216d60d69~mv2.webp)
![NCT04445701: Phase 1/2: Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dex RRMM](https://static.wixstatic.com/media/cd6738_3a04cda6865044f9ac2de8c216d60d69~mv2.jpg/v1/fill/w_268,h_178,fp_0.50_0.50,q_90,enc_auto/cd6738_3a04cda6865044f9ac2de8c216d60d69~mv2.webp)
NCT04445701: Phase 1/2: Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dex RRMM
![](https://static.wixstatic.com/media/cd6738_2218a393d07d491b8b4c4936a3f580c2~mv2.jpeg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/cd6738_2218a393d07d491b8b4c4936a3f580c2~mv2.webp)
![Daratumumab and Hyaluronidase-fihj (Darzalex Faspro) + Lenalidomide (Revlimid) & Dex for RRMM](https://static.wixstatic.com/media/cd6738_2218a393d07d491b8b4c4936a3f580c2~mv2.jpeg/v1/fill/w_268,h_268,fp_0.50_0.50,q_90,enc_auto/cd6738_2218a393d07d491b8b4c4936a3f580c2~mv2.webp)
Daratumumab and Hyaluronidase-fihj (Darzalex Faspro) + Lenalidomide (Revlimid) & Dex for RRMM
![](https://static.wixstatic.com/media/cd6738_a3c132618c234ba2a39e4bcbcda5ceb7~mv2.jpg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/cd6738_a3c132618c234ba2a39e4bcbcda5ceb7~mv2.webp)
![NCCN GUIDELINES FOR PATIENTS: Immunotherapy Side Effects: Immune Checkpoint Inhibitors](https://static.wixstatic.com/media/cd6738_a3c132618c234ba2a39e4bcbcda5ceb7~mv2.jpg/v1/fill/w_268,h_151,fp_0.50_0.50,q_90,enc_auto/cd6738_a3c132618c234ba2a39e4bcbcda5ceb7~mv2.webp)
NCCN GUIDELINES FOR PATIENTS: Immunotherapy Side Effects: Immune Checkpoint Inhibitors